Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Pedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaPedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie
Zmień bibliotekę

Wyszukujesz frazę "Chan, Y.-D." wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-10 z 20
Tytuł:
The large enriched germanium experiment for neutrinoless double beta decay (LEGEND)
Autorzy:
Varner, R. L.
Konovalov, S. I.
Schütz, A.-K.
Shevchik, E.
Meijer, S. J.
Green, M. P.
Harvey, Z. R.
Yu, C.-H.
Hiller, R.
Loomba, D.
Moseev, P.
O'Shaughnessy, C.
Panas, Krzysztof
Rager, J.
Abt, I.
Domula, A.
Miloradovic, M.
Recchia, F.
Pelczar, K.
Vasilyev, S.
Mertens, S.
Peterson, D.
Johansson, H. T.
Lubashevskiy, A.
Zeman, J.
Abramov, A.
Kang, K.
Grabmayr, P.
Shanks, B.
Kish, A.
Lutter, G.
Heinz, A.
Mamedov, F.
Zhitnikov, I.
Golubev, P.
Wagner, M.
Riboldi, S.
Lazzaro, A.
Othman, G.
Sala, E.
Boyd, S. T. P.
Howard, S.
Rukhadze, E.
Zeng, Z.
Schwingenheuer, B.
Garfagnini, A.
Abrosimov, N.
Ajjaq, A.
Lubsandorzhiev, B.
Massarczyk, R.
Mei, H.
Yue, Q.
Fields, D.
Misiaszek, Marcin
Jochum, J.
Abgrall, N.
Yakushev, E.
Schulz, O.
Pandola, L.
Hauertmann, L.
Wester, T.
Kochetov, O.
Balata, M.
Sonay, A.
Egorov, V.
Wójcik, Marcin
Rumyantseva, N.
Simkovic, F.
Veresnikova, A.
Vetter, K.
Radford, D. C.
Wiesinger, C.
Lin, S. T.
Detwiler, J. A.
Myslik, J.
Salamida, F.
Hehn, L.
Du, Q.
Quintana, X. C.
Gold, M.
Giovanetti, G. K.
Papp, L.
Heglund, D.
Zhu, B.
Kermadic, Y.
Wang, G.-J.
Busch, M.
Kröninger, K.
Rielage, K.
Breier, R.
Spavorova, M.
Ma, H.
Csáthy, J. J.
Nemchenok, I.
Chen, S.
Zsigmond, A. J.
Judson, D.
Bai, X.
Cattadori, C.
Reine, A. L.
Elliott, S. R.
Smolek, K.
Wilkerson, J. F.
Zinatulina, D.
Singh, L.
Matthews, J. A. J.
Avignone, F. T.
Zuber, K.
Junker, M.
Van Wechel, T.
Kraetzschmar, T.
Barabanov, I.
Haufe, C. R.
Brudanin, V.
Buuck, M.
Li, H. B.
Kazalov, V.
Miller, W.
Agartioglu, M.
Hult, M.
Cederkäll, J.
Deng, Z.
Gilliss, T.
Liu, J.
Barton, P. J.
Kirsch, A.
Yang, G.
Boston, A.
Schuster, M.
Giordano, M.
Kornoukhov, V. N.
Laubenstein, M.
Mei, D.-M.
Singh, V.
Wei, W.-Z.
Saakyan, R.
Shirchenko, M.
Demidova, E. V.
Hakenmüeller, J.
Caldwell, T. S.
Xu, W.
Chan, Y.-D.
Hofmann, W.
Kontul, I.
Skorokhvatov, M.
Von Sturm, K.
Willers, M.
Hodak, R.
Gangapshev, A.
Smolnikov, A.
Sevda, B.
Janssens, R.
Christofferson, C. D.
Chu, P.-H.
Inzhechik, L. V.
Deniz, M.
Li, Y. L.
Carpenter, M.
Baudis, L.
Cuesta, C.
Schönert, S.
Nilsson, T.
Borowicz, D.
Pullia, A.
Vasenko, A. A.
Boston, H.
Ješkovský, M.
Fischer, F.
Rouf, N. W.
Martin, R. D.
Vorren, K.
Guiseppe, V. E.
Brugnera, R.
Di Marco, N.
Lang, K.
Savard, G.
Wong, H. T.
Zuzel, Grzegorz
Bode, T.
Bolozdynya, A.
Kuzminov, V. V.
Gurentsov, V.
Klimenko, A.
Lippi, I.
Pettus, W.
Barabash, A. S.
Nolan, P.
Selivanenko, O.
Thompson, J.
Alvis, S. I.
Waters, D.
Zschocke, A.
Stukov, D.
Gooch, C.
Chernogorov, A.
Yumatov, V.
Lindner, M.
Gusev, K.
Efremenko, Y.
White, B. R.
Poon, A. W. P.
Harkness-Brennan, L.
Howe, M. A.
Kumar, A.
Liu, S. K.
Agostini, M.
Guinn, I. S.
Hinton, J.
Cooper, R. J.
Majorovits, B.
Stekl, I.
Wiseman, C.
Mingazheva, R.
Gurov, Y.
Kaizer, J.
Caldwell, A.
Liu, X.
Povinec, P. P.
Ransom, C.
Galindo-Uribarri, A.
Kiessling, F.
McFadden, N.
Knöpfle, K. T.
Tedeschi, D.
Sandukovsky, V.
Wyenberg, J.
Bezrukov, L.
Camellato, T.
Li, Y.-Y.
Mengoni, D.
Rozov, S.
Gruszko, J.
Wydawca:
American Institute of Physics
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Inne
Tytuł:
First results on the search for lepton number violating neutrinoless double-$\beta$ decay with the LEGEND-200 experiment
Autorzy:
Deckert, R.
Ianni, A.
Rumyantseva, N.
Solomon, J. A.
Kidd, M. F.
Kontul, I.
Ramachers, Y. A.
Vogl, C.
Nemchenok, I.
Mazumdar, A.
Krause, P.
Chernogorov, A.
Junker, M.
Romo-Luque, C.
Radford, D. C.
Love, A.
Ruland, T. J.
Martin, E. L.
Sousa, A. C.
Lindner, M.
Ackermann, N.
Slavíčková, M.
Lehnert, B.
Alexander, A.
Kilgus, K.
Bos, B.
Hagemann, F.
Rielage, K.
Schwarz, M.
Varriano, L. J.
Lin, Y.-R.
Pruckner, M.
Ye, T.
Canonica, L.
Turqueti, M.
Zinatulina, D.
von Sturm, K.
Bezrukov, L.
Piseri, P.
Sterr, T.
Lay, N. N. P. N.
Vasilyev, S.
Giri, S.
Calgaro, S.
Gruszko, J.
Simonaitis-Boyd, S.
Chan, Y.-D.
Dong, K.-M.
McDowell, G.
Howe, M. A.
Smolnikov, A.
Borghi, G.
Van Nieuwenhuizen, E. E.
Barton, C. J.
Borra, F.
Engelhardt, E.
Gusev, K.
Xu, W.
Di Giacinto, A.
Song, G.
Tretyak, V.
Busch, M.
Comellato, T.
Misiaszek, Marcin
Razeto, A.
Tagnani, D.
Huber, M.
Hinton, J.
Schleich, S. J.
Willers, M.
Veresnikova, A.
Zuber, K.
Baudis, L.
Morgan, B.
Rozov, S.
Lusardi, N.
Schwingenheuer, B.
Schütz, A.-K.
Redchuk, M.
Levashko, N.
Hackett, B.
Herrera, J.
Mróz, Tomasz
Hult, M.
Duran, G.
Bouabid, R.
Lang, K.
Yumatov, V.
Nave, C. J.
Brugnera, R.
Martin, R. D.
Acharya, H.
Pertoldi, L.
Serafini, A.
Geraci, A.
Guinn, I.
Macolino, C.
Schaper, D. C.
Yakushev, E.
Chiu, P.-J.
Reine, A. L.
Dixon, T.
Clark, M. L.
Burlac, N.
Drobizhev, A.
Kihm, T.
Gurentsov, V.
Wiesinger, C.
Kormos, L. L.
Kochanek, I.
Li, L. Y.
Barabash, A. S.
Manzanillas, L.
Fields, D. E.
Salamanna, G.
Stommel, M.
Chapman, J. R.
Di Marco, N.
Febbraro, M. T.
Piastra, F.
Seibt, C.
Wilkerson, J. F.
Xu, D.
Esch, E.
Mirza, I.
Gooch, C.
Shevchik, E.
Wiseman, C.
León, E.
Bauer, C.
Massarczyk, R.
Vignoli, C.
Leonhardt, A.
Harańczyk, Małgorzata
Štekl, I.
Kochetov, O.
Leder, A.
Skorokhvatov, M.
Zuzel, Grzegorz
Schlüter, L.
Agostini, M.
Simgen, H.
Steinhart, L.
Henning, R.
Povinec, P. P.
Henkes, F.
Bernieri, E.
Senatore, G.
Biancacci, V.
Morella, M.
Yu, C.-H.
Gessler, L.
Li, A.
Avignone, F. T.
Shakhov, K.
Shirchenko, M.
Colon-Rivera, A. I.
Waters, D.
Borden, S. J.
Galindo-Uribarri, A.
Fuad, N.
Lippi, I.
Pichotta, M.
Paudel, L. S.
Fomina, M.
Quinn, W. S.
Watkins, S. L.
Krishnamoorthy, H.
Balata, M.
Cesarano, R.
Judson, D. S.
Salamida, F.
Lubashevskiy, A.
Carney, R. M. D.
Meireles, S. P.
Selivanenko, O.
Sullivan, S. A.
Garfagnini, A.
Bakalyarov, A. M.
Capra, S.
Grünauer, G.
Hervas Aguilar, D.
Jędrzejczak, Karol
Cattadori, C.
Jochum, J.
Blalock, E.
Runge, J.
Gurov, Y.
Kornoukhov, V. N.
Pelczar, K.
Pettus, W.
Boston, A.
Bothe, V.
Ghiano, C.
Mamedov, F.
Muenstermann, D.
Elliott, S. R.
Schönert, S.
Schulz, O.
Papp, L.
Green, M. P.
Lubsandorzhiev, B.
Tedeschi, D. J.
Sailer, S.
Warren, A.
Fiorini, C.
Hoffmann, H. F. R.
Kaizer, J.
Thorpe, T. N.
Sreekala, A. R.
Ferella, F.
Saleh, G.
O’Briant, N.
Barbeau, P. S.
Knöpfle, K. T.
Neuberger, M.
Savarese, C.
Hodák, R.
Carminati, M.
Poon, A. W. P.
Menzel, M.
Gangapshev, A.
Emmanuel, C. H. J.
Kazalov, V.
Babicz, M.
Gala, R.
Klimenko, A.
Miller, E.
Sumathi, R. R.
Gieb, A.
Laubenstein, M.
Guiseppe, V. E.
D’Andrea, V.
Mertens, S.
Christofferson, C. D.
Taffarello, L.
Jones, R. W. L.
Šimkovic, F.
Araujo, G. R.
Kuzminov, V. V.
Mei, D.-M.
Paissan, F.
Detwiler, J. A.
Rossi, N.
Szczepaniec, K.
Shitov, Y.
Gold, M.
Efremenko, Yu.
Majorovits, B.
Bhimani, K. H.
Gazzana, S.
Saakyan, R.
Bae, W.
Marshall, G. G.
Riboldi, S.
Pullia, A.
Andreoiu, C.
Wójcik, Marcin
Sandukovsky, V.
Opis:
The LEGEND Collaboration is searching for neutrinoless double-beta ($0\nu\beta\beta$) decay by operating high-purity germanium detectors enriched in $^{76}$Ge in a low-background liquid argon environment. Building on key technological innovations from the GERmanium Detector Array (GERDA) experiment and the MAJORANA DEMONSTRATOR experiment, LEGEND-200 has performed a first $0\nu\beta\beta$ decay search based on 61.0 kg yr of data. Over half of this exposure comes from our highest performing detectors, including newly developed inverted-coaxial detectors, and is characterized by an estimated background level of 0.5$^{+0.3}_{-0.2}$ cts/(keV ton yr) in the $0\nu\beta\beta$ decay signal region. A combined analysis of data from GERDA, the MAJORANA DEMONSTRATOR, and LEGEND-200, characterized by a 90% confidence level exclusion sensitivity of 2.8 $\times$ 10$^{26}$ yr on the half-life of $0\nu\beta\beta$ decay, reveals no evidence for a signal and sets a new observed lower limit at $T^{0\nu}_{1/2}$ > 1.0 $\times$ 10$^{26}$ yr (90% confidence level). Assuming the decay is mediated by Majorana neutrinos, this corresponds to an upper limit on the effective Majorana mass in the range $m_{\beta\beta}$ < 75-200 meV, depending on the adopted nuclear matrix element.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
Carrier Dynamics and Dynamic Band-Bending in Type-II ZnTe/ZnSe Quantum Dots
Autorzy:
Syperek, M.
Misiewicz, J.
Chan, C.
Dumcenco, D.
Huang, Y.
Chou, W.
Tematy:
78.67.Hc
78.55.Et
78.47.J-
Pokaż więcej
Wydawca:
Polska Akademia Nauk. Instytut Fizyki PAN
Powiązania:
https://bibliotekanauki.pl/articles/1399095.pdf  Link otwiera się w nowym oknie
Opis:
Carrier dynamics and dynamic band-bending in self-assembled ZnTe/ZnSe quantum dots have been studied by means of time-resolved photoluminescence experiment at low temperatures. The experiment reveals clearly type-II character of the confinement potential in the dot manifested in: (i) long photoluminescence decay time constant of 28-35 ns, and (ii) temporal shift of the quantum dot peak emission towards low energy following the laser pulse excitation. The magnitude of the spectral shift Δ E depends on the dot size and the power density of excitation pulse. For the dots under study and given experimental conditions Δ E ≈ 28 ÷ 42 meV.
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Autorzy:
Cheah, Chan Y.
Chavez, Julio C.
Sharman, Jeff P.
Miskin, Hari P.
Hodson, Daniel J.
Leslie, Lori A.
Babu, Sunil
Cheson, Bruce D.
Oconnor, Owen A.
Weiss, Michael S.
Law, Jennie Y.
Samaniego, Felipe
Jurczak, Wojciech
Grosicki, Sebastian
Derenzini, Enrico
Reeves, James A.
Knopinśka-Posłuszny, Wanda
Phillips, Tycel
Lech-Maranda, Ewa
Ghosh, Nilanjan
Burke, John M.
Fonseca, Gustavo
Zinzani, Pier Luigi
Shao, Spencer H.
Pagel, John M.
Fowler, Nathan H.
Caimi, Paolo F.
Sportelli, Peter
Opis:
Purpose: Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein kinase-1ε, exhibits improved selectivity for PI3Kδ compared with other PI3K inhibitors. This phase IIb trial was designed to evaluate the efficacy and safety of umbralisib in patients with R/R iNHL. Patients and Methods; In this multicohort, open-label, phase IIb study, 208 patients with R/R marginal zone, follicular, or small lymphocytic lymphoma (MZL, FL, or SLL) unresponsive to prior treatments (≥ 1 MZL; ≥ 2 FL/SLL), including ≥ 1 anti-CD20–based therapy, were administered umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal. Primary end point is overall response rate; secondary end points include time to response, duration of response, progression-free survival, and safety. Results; The median follow-up is 27.7 months (efficacy) and 21.4 months (safety). The overall response rate was 47.1%, and tumor reduction occurred in 86.4% of patients. The median time to response was 2.7-4.6 months. The median duration of response was not reached for MZL, 11.1 months for FL, and 18.3 months for SLL. Median progression-free survival was not reached for MZL, 10.6 months for FL, and 20.9 months for SLL. At least one grade ≥ 3 treatment-emergent adverse event (TEAE) was reported in 53.4% of patients. TEAEs led to umbralisib discontinuation in 32 patients (15.4%). A total of 31 patients (14.9%) discontinued because of a treatment-related adverse event. Grade ≥ 3 TEAEs reported in ≥ 10% of patients: neutropenia (11.5%) and diarrhea (10.1%). Increased ALT/AST (grade ≥ 3) occurred in 6.7%/7.2% of patients. Conclusion; Umbralisib achieved meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event–related discontinuations.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Autorzy:
Dimopoulos, Meletios A.
Ji, Meng
D'Sa, Shirley
Cohen, Aileen
Xu, Wei
Tam, Constantine S
Huang, Jane
Garcia-Sanz, Ramon
Roberts, Andrew W
Zhu, Jun
Li, Jianyong
Marlton, Paula
Guo, Haiyi
Song, Yuqin
Jurczak, Wojciech
Gottlieb, David J
Zhou, Lei
Munoz, Javier
Du, Chenmu
Phillips, Tycel
Novotny, William
Cull, Gavin
Owen, Roger G.
Zhu, Hongjie
Tedeschi, Alessandra
Trotman, Judith
Chan, Wai Y.
Qiu, Lugui
Opat, Stephen
Opis:
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were pooled from 6 studies (N=779). Assessments included type, incidence, severity, and outcome of TEAEs. Median age was 65 years; 20% were ≥75 years old. Most patients had Waldenström macroglobulinemia (33%), chronic lymphocytic leukemia/small lymphocytic lymphoma (29%), or mantle-cell lymphoma (19%). Median treatment duration was 26 months (range: 0.1-65); 16% of patients were treated for ≥3 years. Common nonhematologic TEAEs were upper respiratory tract infection (URI, 39%), rash (27%), bruising (25%), musculoskeletal pain (24%), diarrhea (23%), cough, pneumonia (21% each), urinary tract infection (UTI), fatigue (15% each). Most common grade ≥3 TEAEs were pneumonia (11%), hypertension (5%), URI, UTI, sepsis, diarrhea, and musculoskeletal pain (2% each). Atrial fibrillation and major hemorrhage occurred in 3% and 4% of patients, respectively. Atrial fibrillation, hypertension and diarrhea occurred at lower rates than those reported historically for ibrutinib. Grade ≥3 AEs included neutropenia (23%), thrombocytopenia (8%), and anemia (8%). Serious TEAEs included pneumonia (11%), sepsis (2%), and pyrexia (2%). Treatment discontinuations and dose reductions for AEs occurred in 10% and 8% of patients, respectively. Thirty-nine patients (4%) had fatal TEAEs, including pneumonia (n=9), sepsis (n=4), unspecified cause (n=4), and multiple organ dysfunction syndrome (n=5). This analysis demonstrates that zanubrutinib is generally well tolerated with a safety profile consistent with known BTK inhibitor toxicities; these were manageable and mostly reversible.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
An optical gamma-ray burst catalogue with measured redshift : I. Data release of 535 gamma-ray bursts and colour evolution
Autorzy:
Rossi, A.
Oates, S. R.
Orange, N. B.
Moriya, T. J.
Rinaldi, E.
Fraija, N.
Lopresti, C.
Jamal, W.
González, J. d. J. G.
Gendre, B.
Prochaska, X.
Levine, D.
Kumar, R.
Rosi, P.
Castro-Tirado, A. J.
Becerra, R. L.
Conti, M.
Pozanenko, A.
Das, U.
Richer, M.
Strabla, L.
Butler, N. R.
Saha, N.
Misra, K.
Niino, Y.
do E. S. Pedreira, A. C. C.
Kido, D.
Watson, A. M.
Volnova, A.
Kutyrev, A. S.
Ramirez, L. M. T.
Zoła, Stanisław
Lee, W. H.
Quadri, U.
Ruocco, N.
Li, L.
Dainotti, M. G.
Desai, S.
Pasumarti, V.
Siegel, M. H.
Kalinowski, K. K.
Lambiase, G.
De Simone, B.
Leonini, S.
Chan, L.
Hu, Y -D.
Jindal, I.
Cenko, S. B.
Fuentes, M.
Ramirez-Ruiz, E.
Belkin, S.
Mohideen Malik, R. F.
Opis:
We present the largest optical photometry compilation of gamma-ray bursts (GRBs) with redshifts (z). We include 64813 observations of 535 events (including upper limits) from 28 February 1997 to 18 August 2023. We also present a user-friendly web tool grbLC which allows users to visualize photometry, coordinates, redshift, host galaxy extinction, and spectral indices for each event in our database. Furthermore, we have added a Gamma-ray Coordinate Network (GCN) scraper that can be used to collect data by gathering magnitudes from the GCNs. The web tool also includes a package for uniformly investigating colour evolution. We compute the optical spectral indices for 138 GRBs, for which we have at least four filters at the same epoch in our sample, and craft a procedure to distinguish between GRBs with and without colour evolution. By providing a uniform format and repository for the optical catalogue, this web-based archive is the first step towards unifying several community efforts to gather the photometric information for all GRBs with known redshifts. This catalogue will enable population studies by providing light curves (LCs) with better coverage since we have gathered data from different ground-based locations. Consequently, these LCs can be used to train future LC reconstructions for an extended inference of the redshift. The data gathering also allows us to fill some of the orbital gaps from Swift in crucial points of the LCs, e.g. at the end of the plateau emission or where a jet break is identified.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia : final analysis from the randomized phase III ASPEN study
Autorzy:
Dimopoulos, Meletios A.
McCarthy, Helen
Trneny, Marek
D'Sa, Shirley
Cohen, Aileen
Motta, Marina
Mulligan, Stephen
Wahlin, Bjorn E.
Schneider, Jingjing
Tam, Constantine S.
Fernández de Larrea, Carlos
Garcia-Sanz, Ramon
Allewelt, Heather
Buske, Christian
Czyz, Jaroslaw
Marlton, Paula
Libby, Edward
Tani, Monica
Jurczak, Wojciech
Opat, Stephen
Siddiqi, Tanya
Patel, Sheel
Cull, Gavin
Owen, Roger G.
Leblond, Veronique
Belada, David
Castillo, Jorge J.
Tedeschi, Alessandra
Treon, Steven P.
Trotman, Judith
Chan, Wai Y.
Lee, Hui-Peng
Minnema, Monique C.
Matous, Jeffrey
Opis:
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. The primary end point was the sum of very good partial response (VGPR) + complete response (CR) rates; secondary and exploratory end points were also reported. Cohort 1 comprised 201 patients (myeloid differentiation primary response 88–mutant WM: 102 receiving zanubrutinib; 99 receiving ibrutinib); cohort 2 comprised 28 patients (myeloid differentiation primary response 88 wild-type WM: 28 zanubrutinib; 26 efficacy evaluable). At 44.4-month median follow-up, VGPR + CR rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in cohort 1 and 30.8% with one CR in cohort 2. In patients with CXC motif chemokine receptor 4 mutation, VGPR + CR rates were 21.2% with zanubrutinib versus 10.0% with ibrutinib (cohort 1). Median progression-free survival and overall survival were not reached. Any-grade adverse events (AEs) of diarrhea (34.7% v 22.8%), muscle spasms (28.6% v 11.9%), hypertension (25.5% v 14.9%), atrial fibrillation/flutter (23.5% v 7.9%), and pneumonia (18.4% v 5.0%) were more common with ibrutinib versus zanubrutinib; neutropenia (20.4% v 34.7%) was less common with ibrutinib versus zanubrutinib (cohort 1). Zanubrutinib was associated with lower risk of AE-related treatment discontinuation. Overall, these findings confirm the long-term response quality and tolerability associated with zanubrutinib.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Wyświetlanie 1-10 z 20

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies